TNFRSF1B and breast cancer: Indeed, inhibiting the binding of TNFR2 and its ligand TNF-α through high-affinity antibodies, especially in the CRD regions where both proteins interact the most, is crucial to eliminating the burden of TNFR2 as an immunosuppressive protein in the BC TME.